Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 13 June 2018

Indication(s)

- NovoMix 30 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 30 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.



- NovoMix 50 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 50 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 50 is indicated for treatment of diabetes mellitus in adults.



- NovoMix 70 Penfill 100 units/ml suspension for injection in cartridge
- NovoMix 70 FlexPen 100 units/ml suspension for injection in pre-filled pen


NovoMix 70 is indicated for treatment of diabetes mellitus in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Alkaline Phosphatase (ALP) Lab Assessment

Alkaline Phosphatase (ALP) Lab Assessment

Discover an overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000308
Orphan designation No
Date First Approved 01-08-2000
Type Medicinal product subject to medical prescription
Marketing authorisation holder Novo Nordisk A/S